TWOEquity · Weekly research terminal

7595

Pharmigene, Inc.

TW Healthcare Diagnostics & Research

Latest week
14 Aug 2026
Weekly close
7.25 TWD
Fair value
14.70 TWD
Next-week expectancy
Negative 35.98%
Crowd view
Current verdict No votes yet Be first to vote

Sharemaestro
Weekly Chart Pack Completed weekly market data · Independent research

TWO · Equity · Taiwan

7595

Pharmigene, Inc.

Healthcare Diagnostics & Research

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variations; whole-genome precision annotation platform; single-cell and …

Last updated
14 Aug 2026
Exchange
Taipei Exchange · TWO
Sector
Healthcare
Industry
Diagnostics & Research
Currency
TWD
Market capitalisation
365,871,264
Fair value reference
14.70
Next-week expectancy
Negative · 35.98%

Over the latest 12 completed weeks ending 2026-08-14, 7595 fell 18.99%, moving from 8.95 to 7.25. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is -49.73 and has softened across the 12-week window. Market Dynamics is -0.73 on the latest week. Next-week expectancy is negative at 35.98% based on similar historical setup states.

Week Ending
14 Aug 2026
Latest Close
7.25
12-Week Change
-18.99%
Trend Signal
Inactive
Next-Week Expectancy
Negative 35.98%
Signal Weeks
0 of 12

Weekly Price

Weekly Close Trend Line Fair Value Activity Lines

Chart Panels

Choose up to 5 panels. Drag panel headers to reorder.

Chart Summary

Key Points

Week Ending
14 Aug 2026
Latest Close
7.25
12-Week Change
-18.99%
Trend Signal
Inactive
Next-Week Expectancy
Negative 35.98%
Signal Weeks
0 of 12
Vs Trend Line
Below
Vs Fair Value
Below
Relative Strength
-49.73
Market Dynamics
-0.73

Over the latest 12 completed weeks ending 2026-08-14, 7595 fell 18.99%, moving from 8.95 to 7.25. The latest weekly close is below the Trend Line and below Fair Value. Trend Signal is inactive on the latest week and was active in 0 of the last 12 weeks. Relative Strength is -49.73 and has softened across the 12-week window. Market Dynamics is -0.73 on the latest week. Next-week expectancy is negative at 35.98% based on similar historical setup states.

Industry Peers

Taiwan equities in Diagnostics & Research

Stock Exchange Week Open High Low Close Change
6847 Puriblood Medical Co., Ltd. TWO 14 Aug 2026 77.70 81.40 75.80 79.30 2.06%
6939 TFBS Bioscience Inc. TWO 14 Aug 2026 19.50 20.00 18.70 19.65 0.77%
1784 BIONET Corp. TWO 14 Aug 2026 60.20 62.90 60.20 60.60 0.66%
4160 Genetics Generation Advancement Corp. TWO 14 Aug 2026 40.15 41.00 39.40 39.80 -0.87%
6615 Sofiva Genomics Co.,Ltd. TWO 14 Aug 2026 34.20 34.60 33.45 33.75 -1.32%
4153 DIVA Laboratories, Ltd. TWO 14 Aug 2026 33.45 33.45 32.40 33.00 -1.35%
6645 Kim Forest Enterprise Co., Ltd. TAI 14 Aug 2026 13.55 13.60 13.10 13.25 -2.21%
6661 Welgene Biotech Co.,Ltd. TWO 14 Aug 2026 17.60 17.60 16.00 16.75 -4.83%

Next-week expectancy

Next-week expectancy is a short-term historical read. It compares the latest completed-week setup with broadly similar past setups and asks whether the following week tended to close higher or lower.

It is not a trend call, a price target, or a guarantee. A positive read can appear while price is below trend or activity pressure is weak, because it is measuring short-term follow-through odds for the current setup state.

Use it as one context layer beside Trend Line, Relative Strength, Market Dynamics, Fair Value, and the visible price structure.

Evidence context